Cited by 293Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and LipoproteinsDiabetes Management and Research

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin

Open access

Evans, J. M. M., Ogston, S. A., Emslie-Smith, A., Morris, A. D.·2006·Diabetologia

DOI 10.1007/s00125-006-0176-9

Open this paper in CoChat — free account Open PDF

Abstract

Aims/hypothesis The aim of this study was to evaluate the risk of adverse cardiovascular outcomes in patients with type 2 diabetes newly treated with sulfonylureas and metformin.Subjects and methods The Diabetes Audit and Research in Tayside Scotland (DARTS) diabetes information system and the Medicines Monitoring Unit (MEMO) dispensed prescribing database for the population of Tayside, Scotland (400,000 people) were employed. Patients newly prescribed with oral hypoglycaemic agents between 1994 and 2001 were classified into five study cohorts according to the treatment received: metformin only, sulfonylureas only, sulfonylureas added to metformin, metformin added to sulfonylureas, and both drugs simultaneously. In Cox regression analyses, we estimated relative risks for all-cause mortality, cardiovascular mortality and cardiovascular hospital admission for patients in the five study cohorts, with metformin monotherapy as the reference group.Results Of the 5,730 study patients, 1,000 died during a maximum of 8 years follow-up. Patients in the sulfonylureas only cohort had increased risks of mortality and cardiovascular mortality, with unadjusted relative risks of 3.12 (95% CI 2.54-3.84) and 3.71 (95% CI 2.64-5.22), respectively. After adjusting for differences between groups (age, sex, duration of diabetes, blood pressure, cholesterol, HbA(1c), smoking, previous hospital admission, treatment with cardiovascular medication), these relative risks were 1.43 (95% CI 1.15-1.77) and 1.70 (95% CI 1.18-2.45), respectively. Patients in the combination cohorts had significantly increased risks of cardiovascular hospital admission, as well as increased risks of mortality and cardiovascular mortality.Conclusions/interpretation In this cohort study of patients newly treated with oral hypoglycaemic agents, those treated with sulfonylureas only, or combinations of sulfonylureas and metformin, were at higher risk of adverse cardiovascular outcomes than those treated with metformin alone.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1007/s00125-006-0176-9

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07037-8 · Cited by 8,247
Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infarction
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
(1998) · PubMed · Cited by 4,290
Dietary Advanced Glycation End Products and Their Potential Role in Cardiometabolic Disease in Children
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,023
International statistical classification of diseases and related health problems. Tenth revision.
Brämer, G. R. (1988) · PubMed · Cited by 1,492
Deprivation and Health in Scotland
Tunstall-Pedoe, H. (1993) · Postgraduate Medical Journal · doi:10.1136/pgmj.69.814.665-a · Cited by 1,171
Manual of the International Statistical Classification of Diseases, Injuries, and Causes of Death.
Schneider, B. A. (1953) · The Quarterly Review of Biology · doi:10.1086/399926 · Cited by 1,000
Decreased Mortality Associated With the Use of Metformin Compared With Sulfonylurea Monotherapy in Type 2 Diabetes
Johnson, J. A., Majumdar, S. R., Simpson, S. H., & Toth, E. L. (2002) · Diabetes Care · doi:10.2337/diacare.25.12.2244 · Cited by 421
The diabetes audit and research in Tayside Scotland (darts) study: electronic record linkage to create a diabetes register
Morris, A. D., Boyle, D. I., MacAlpine, R., Emslie-Smith, A. M., Jung, R. T., Newton, R. W., & MacDonald, T. M. (1997) · BMJ · doi:10.1136/bmj.315.7107.524 · Cited by 297
Self-citation

Flagged first, then by citations

Show all 19 references

Sorted by citations

From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus.
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Tumor cell metabolism: cancer's Achilles' heel
Kroemer, G., & Pouyssegur, J. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.05.005 · Cited by 2,337
New Users of Metformin Are at Low Risk of Incident Cancer
Libby, G., Donnelly, L. A., Donnan, P. T., Alessi, D. R., Morris, A. D., & Evans, J. M. M. (2009) · Diabetes Care · doi:10.2337/dc08-2175 · Cited by 996
Self-citation
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter (posthumous), E. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002967.pub4 · Cited by 893
Interaction of Cardiovascular Risk Factors with Myocardial Ischemia/Reperfusion Injury, Preconditioning, and Postconditioning
Ferdinandy, P., Schulz, R., & Baxter, G. F. (2007) · Pharmacological Reviews · doi:10.1124/pr.107.06002 · Cited by 752
Anti-inflammatory effects of metformin irrespective of diabetes status
Cameron, A. R., Morrison, V. L., Levin, D., Mohan, M., Forteath, C., Beall, C., McNeilly, A. D., Balfour, D. J. K., Savinko, T., Wong, A. K. F., et al. (2016) · Circulation Research · doi:10.1161/circresaha.116.308445 · Cited by 704
Metformin: An Old But Still the Best Treatment for Type 2 Diabetes
Rojas, L. B. A., & Gomes, M. B. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-6 · Cited by 567
mTOR Complex1–S6K1 signaling: at the crossroads of obesity, diabetes and cancer
Dann, S. G., Selvaraj, A., & Thomas, G. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.04.002 · Cited by 481
Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: A systematic review and meta-analysis
Campbell, J. M., Bellman, S. M., Stephenson, M. D., & Lisy., K. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.08.003 · Cited by 455
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database
Tzoulaki, I., Molokhia, M., Curcin, V., Little, M. P., Millett, C. J., Ng, A., Hughes, R. I., Khunti, K., Wilkins, M. R., Majeed, A., et al. (2009) · BMJ · doi:10.1136/bmj.b4731 · Cited by 444
Long-term Effects of Metformin on Metabolism and Microvascular and Macrovascular Disease in Patients With Type 2 Diabetes Mellitus
Kooy, A., de Jager, J., Lehert, P., Bets, D., Wulffelé, M. G., Donker, A. J. M., & Stehouwer, C. D. A. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.20 · Cited by 440
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter, E. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002967.pub3 · Cited by 447
Guidelines for the management of chronic kidney disease
Levin, A., Hemmelgarn, B. R., Culleton, B. F., Tobe, S. W., McFarlane, P., Ruzicka, M., Burns, K. D., Manns, B., White, C., Madore, F., et al. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.080351 · Cited by 428
Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline From the American College of Physicians
Qaseem, A., Humphrey, L. L., Sweet, D. E., Starkey, M., & Shekelle, P. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-3-201202070-00011 · Cited by 401
Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Coronary Artery Disease
Hong, J., Zhang, Y., Lai, S., Lv, A., Su, Q., Dong, Y., Zhou, Z., Tang, W., Zhao, J., Cui, L., et al. (2013) · Diabetes Care · doi:10.2337/dc12-0719 · Cited by 366
Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls
Bannister, C. A., Holden, S. E., Jenkins‐Jones, S., Morgan, C. L., Halcox, J. P., Schernthaner, G., Mukherjee, J., & Currie, C. J. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12354 · Cited by 356
Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis
Han, Y., Xie, H., Liu, Y., Gao, P., Yang, X., & Shen, Z. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0900-7 · Cited by 337
The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell–Centric Classification Schema
Schwartz, S. S., Epstein, S., Corkey, B. E., Grant, S. F. A., Gavin, J. R., & Aguilar, R. B. (2016) · Diabetes Care · doi:10.2337/dc15-1585 · Cited by 361
Metformin therapy and clinical uses
Scarpello, J. H., & Howlett, H. C. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.027 · Cited by 318
Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
DeFronzo, R. A., Eldor, R., & Abdul‐Ghani, M. A. (2013) · Diabetes Care · doi:10.2337/dcs13-2011 · Cited by 323
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
Ferrannini, E., & DeFronzo, R. A. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv239 · Cited by 265
Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association–European Society of Cardiology
Maack, C., Lehrke, M., Backs, J., Heinzel, F. R., Hulot, J., Marx, N., Paulus, W. J., Rossignol, P., Taegtmeyer, H., Bauersachs, J. K., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy596 · Cited by 255
Mortality risk among sulfonylureas: a systematic review and network meta-analysis
Simpson, S. H., Lee, J., Choi, S., Vandermeer, B., Abdelmoneim, A. S., & Featherstone, T. R. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70213-x · Cited by 223
Lactic Acidosis Induced by Metformin
Lalau, J. (2010) · Drug Safety · doi:10.2165/11536790-000000000-00000 · Cited by 221
Is the Combination of Sulfonylureas and Metformin Associated With an Increased Risk of Cardiovascular Disease or All-Cause Mortality?
Rao, A. D., Kuhadiya, N. D., Reynolds, K., & Fonseca, V. A. (2008) · Diabetes Care · doi:10.2337/dc08-0167 · Cited by 208
Metabolic disease in HIV infection
Lake, J. E., & Currier, J. S. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70271-8 · Cited by 198
Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-Regression Analysis of the Observational Studies
Azoulay, L., & Suissa, S. (2017) · Diabetes Care · doi:10.2337/dc16-1943 · Cited by 195
Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial
Göke, B., Gallwitz, B., Eriksson, J. G., Hellqvist, Å., Gause‐Nilsson, I. A. M., & for the D1680C00001 Investigators (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02510.x · Cited by 172
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter, E. E. (2006) · The Cochrane Database of Systematic Reviews (Complete Reviews) · doi:10.1002/14651858.cd002967.pub2 · Cited by 163
Sulphonylureas and risk of cardiovascular disease: systematic review and meta‐analysis
Phung, O. J., Schwartzman, E., Allen, R. W., Engel, S. S., & Rajpathak, S. N. (2013) · Diabetic Medicine · doi:10.1111/dme.12232 · Cited by 153
Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA trial
Rosenstock, J., Marx, N., Kahn, S. E., Zinman, B., Kastelein, J. J. P., Lachin, J. M., Bluhmki, E., Patel, S. D., Johansen, O.-E., & Woerle, H. J. (2013) · Diabetes and Vascular Disease Research · doi:10.1177/1479164112475102 · Cited by 143
Metformin: Effects on Micro and Macrovascular Complications in Type 2 Diabetes
Bailey, C. J. (2008) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-008-6092-0 · Cited by 138
Optical control of insulin release using a photoswitchable sulfonylurea
Broichhagen, J., Schönberger, M., Cork, S. C., Frank, J. A., Marchetti, P., Bugliani, M., Shapiro, A. M. J., Trapp, S., Rutter, G. A., Hodson, D. J., et al. (2014) · Nature Communications · doi:10.1038/ncomms6116 · Cited by 136
Megatrials in type 2 diabetes. From excitement to frustration?
Prato, S. D. (2009) · Diabetologia · doi:10.1007/s00125-009-1352-5 · Cited by 128
New Drugs for Type 2 Diabetes Mellitus
Krentz, A. J., Patel, M., & Bailey, C. J. (2008) · Drugs · doi:10.2165/00003495-200868150-00005 · Cited by 122
Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study
Douros, A., Dell’Aniello, S., Yu, O. H. Y., Filion, K. B., Azoulay, L., & Suissa, S. (2018) · BMJ · doi:10.1136/bmj.k2693 · Cited by 125
Coexpression of the Type 2 Diabetes Susceptibility Gene Variants KCNJ11 E23K and ABCC8 S1369A Alter the ATP and Sulfonylurea Sensitivities of the ATP-Sensitive K+ Channel
Hamming, K. S. C., Soliman, D., Matemisz, L. C., Niazi, O., Lang, Y. V., Gloyn, A. L., & Light, P. E. (2009) · Diabetes · doi:10.2337/db09-0143 · Cited by 117
Combine and conquer: advantages and disadvantages of fixed‐dose combination therapy
Bell, D. S. H. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12015 · Cited by 119
Dietary Interventions to Extend Life Span and Health Span Based on Calorie Restriction
Minor, R. K., Allard, J. S., Younts, C. M., Ward, T. M., & de Cabo, R. (2010) · The Journals of Gerontology Series A · doi:10.1093/gerona/glq042 · Cited by 113
Cardiovascular disease and glycemic control in type 2 diabetes: now that the dust is settling from large clinical trials
Giorgino, F., Leonardini, A., & Laviola, L. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12044 · Cited by 113
Are sulphonylureas all the same? A cohort study on cardiovascular and cancer‐related mortality
Monami, M., Balzi, D., Lamanna, C., Barchielli, A., Masotti, G., Buiatti, E., Marchionni, N., & Mannucci, E. (2007) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.736 · Cited by 111
Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis
Engel, S. S., Golm, G. T., Shapiro, D., Davies, M. J., Kaufman, K. D., & Goldstein, B. J. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-3 · Cited by 98
Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis
Schernthaner, G., Barnett, A. H., Betteridge, D. J., Carmena, R., Ceriello, A., Charbonnel, B. H., Hanefeld, M., Lehmann, R., Malecki, M. T., Nesto, R. W., et al. (2010) · Diabetologia · doi:10.1007/s00125-010-1702-3 · Cited by 97
Effect of Metformin on Mortality in Patients With Heart Failure and Type 2 Diabetes Mellitus
Evans, J. M. M., Doney, A. S. F., AlZadjali, M. A., Ogston, S. A., Petrie, J. R., Morris, A. D., Struthers, A. D., Wong, A., & Lang, C. C. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.05.031 · Cited by 95
Self-citation
Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study
Eurich, D. T., Simpson, S. H., Senthilselvan, A., Asche, C. V., Sandhu-Minhas, J. K., & McAlister, F. A. (2013) · BMJ · doi:10.1136/bmj.f2267 · Cited by 93
Medical Antihyperglycaemic Treatment of Type 2 Diabetes Mellitus
Matthaei, S., Bierwirth, R., Fritsche, A., Gallwitz, B., Häring, H., Joost, H., Kellerer, M., Kloos, C., Kunt, T., Nauck, M. A., et al. (2009) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0029-1239559 · Cited by 93
The Role of Metformin in Metformin-Associated Lactic Acidosis (MALA): Case Series and Formulation of a Model of Pathogenesis
Duong, J. K., Furlong, T. J., Roberts, D. M., Graham, G. G., Greenfield, J. R., Williams, K. M., & Day, R. O. (2013) · Drug Safety · doi:10.1007/s40264-013-0038-6 · Cited by 91
Mechanisms of action of metformin with special reference to cardiovascular protection
Zilov, A. V., Abdelaziz, S. I., Alshammary, A., Zahrani, A. A., Amir, A., Khalil, S. H. A., Brand, K. M. G., Elkafrawy, N., Hassoun, A. A. K., Jahed, S. A., et al. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3173 · Cited by 89
Variations in tissue selectivity amongst insulin secretagogues: a systematic review
Abdelmoneim, A. S., Hasenbank, S., Seubert, J. M., Brocks, D. R., Light, P. E., & Simpson, S. H. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01496.x · Cited by 88
Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin—based therapies
Ban, K., Hui, S., Drucker, D. J., & Husain, M. (2009) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2009.04.001 · Cited by 85
The Risk of Overall Mortality in Patients With Type 2 Diabetes Receiving Glipizide, Glyburide, or Glimepiride Monotherapy
Pantalone, K. M., Kattan, M. W., Yu, C., Wells, B. J., Arrigain, S., Jain, A., Atreja, A., & Zimmerman, R. S. (2010) · Diabetes Care · doi:10.2337/dc10-0017 · Cited by 87
Association of sulphonylurea treatment with all-cause and cardiovascular mortality: A systematic review and meta-analysis of observational studies
Forst, T. M., Hanefeld, M., Jacob, S., Moeser, G., Schwenk, G., Pfützner, A., & Haupt, A. (2013) · Diabetes and Vascular Disease Research · doi:10.1177/1479164112465442 · Cited by 86
Treating type 2 diabetes: how safe are current therapeutic agents?
Philippé, J., & Raccah, D. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01980.x · Cited by 87
Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial
Holman, R. R., Paul, S., Farmer, A., Tucker, L., Stratton, I. M., Neil, H. A. W., & on behalf of the AFORRD study group (2009) · Diabetologia · doi:10.1007/s00125-008-1179-5 · Cited by 81
Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events
Rosenstock, J., Marx, N., Neubacher, D., Seck, T. L., Patel, S. D., Woerle, H., & Johansen, O. E. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0215-2 · Cited by 81
Micro–RNA-126 Reduces the Blood Thrombogenicity in Diabetes Mellitus via Targeting of Tissue Factor
Witkowski, M., Weithauser, A., Tabaraie, T., Steffens, D., Kränkel, N., Witkowski, M., Stratmann, B., Tschoepe, D., Landmesser, U., & Rauch-Kroehnert, U. (2016) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.306094 · Cited by 79
Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer
Abdelmoneim, A. S., Eurich, D. T., Light, P. E., Senior, P. A., Seubert, J. M., Makowsky, M. J., & Simpson, S. H. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12456 · Cited by 78
Cardiovascular risk following metformin treatment in patients with type 2 diabetes mellitus: Results from meta-analysis
Zhang, K., Yang, W., Dai, H., & Deng, Z. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108001 · Cited by 80
Concurrent diabetes and heart failure: interplay and novel therapeutic approaches
Karwi, Q. G., Ho, K. L., Pherwani, S., Ketema, E. B., Sun, Q., & Lopaschuk, G. D. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab120 · Cited by 80
Severe sulfonylurea-induced hypoglycemia: a problem of uncritical prescription and deficiencies of diabetes care in geriatric patients
Holstein, A., Hammer, C., Hahn, M., Kulamadayil-Heidenreich, N. S. A., & Kovacs, P. L. (2010) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2010.492777 · Cited by 74
Metformin and Vitamin B12 Deficiency: Where Do We Stand?
Ahmed, M. A. (2016) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3pk7p · Cited by 78
Type 2 diabetes mellitus—current therapies and the emergence of surgical options
Lebovitz, H. E. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.10 · Cited by 69
Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add‐on to metformin in patients with type 2 diabetes
Müller‐Wieland, D., Kellerer, M., Cypryk, K., Skripova, D., Rohwedder, K., JOHNSSON, E. K., García‐Sánchez, R., Kurlyandskaya, R., Sjöström, C. D., Jacob, S., et al. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13437 · Cited by 68
Association of Metformin Treatment with Reduced Severity of Diabetic Retinopathy in Type 2 Diabetic Patients
Li, Y., Ryu, C. L., Munie, M., Noorulla, S., Rana, S., Edwards, P. A., Gao, H., & Qiao, X. (2018) · Journal of Diabetes Research · doi:10.1155/2018/2801450 · Cited by 68
Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm
Abdul-Ghani, M. A., & DeFronzo, R. A. (2017) · Diabetes Care · doi:10.2337/dc16-2368 · Cited by 64
Sulfonylurea Use and Incident Cardiovascular Disease Among Patients With Type 2 Diabetes: Prospective Cohort Study Among Women
Li, Y., Hu, Y., Ley, S. H., Rajpathak, S. N., & Hu, F. B. (2014) · Diabetes Care · doi:10.2337/dc14-1306 · Cited by 65
Risk of severe hypoglycemia in sulfonylurea‐treated patients from diabetes centers in Germany/Austria: How big is the problem? Which patients are at risk?
Schloot, N. C., Haupt, A., Schütt, M., Badenhoop, K. W. J., Laimer, M. W., Nicolay, C., Reaney, M. D., Fink, K., & Holl, R. W. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2722 · Cited by 62
Explaining the Decline in Early Mortality in Men and Women With Type 2 Diabetes
Charlton, J., Latinovic, R., & Gulliford, M. C. (2008) · Diabetes Care · doi:10.2337/dc08-0137 · Cited by 60
Observational studies of the association between glucose-lowering medications and cardiovascular outcomes: addressing methodological limitations
Patorno, E., Patrick, A. R., Garry, E. M., Schneeweiß, S., Gillet, V. G., Bartels, D. B., Massó-González, E. L., & Seeger, J. D. (2014) · Diabetologia · doi:10.1007/s00125-014-3364-z · Cited by 60
Effects of metformin plus gliclazide compared with metformin alone on circulating endothelial progenitor cell in type 2 diabetic patients
Chen, L., Liao, Y.-F., Zeng, T., Fan, Y., Li, H., & Feng, Y. (2010) · Endocrine · doi:10.1007/s12020-010-9383-8 · Cited by 59
Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy
Wheeler, S., Moore, K. P., Forsberg, C. W., Riley, K., Floyd, J. S., Smith, N. L., & Boyko, E. J. (2013) · Diabetologia · doi:10.1007/s00125-013-2958-1 · Cited by 56
Glibenclamide-related excess in total and cardiovascular mortality risks: Data from large Ukrainian observational cohort study
Khalangot, M. D., Tronko, M. D., Kravchenko, V. I., & Kovtun, V. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.09.008 · Cited by 56
Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)‐TIMI 53 trial
Mosenzon, O., Raz, I., Scirica, B. M., Hirshberg, B., Stahre, C., Steg, P. G., Davidson, J. A., Öhman, P., Price, D. L., Frederich, B., et al. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2413 · Cited by 51
Hypoxia and Metabolism in Cancer
Bensaad, K., & Harris, A. L. (2013) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-5915-6_1 · Cited by 49
Cancer Risk in Type 2 Diabetes Mellitus: Metabolic Links and Therapeutic Considerations
Sun, G. E. C., & Kashyap, S. R. (2011) · Journal of Nutrition and Metabolism · doi:10.1155/2011/708183 · Cited by 51
Where Does Metformin Stand in Modern Day Management of Type 2 Diabetes?
Ahmad, E., Sargeant, J. A., Zaccardi, F., Khunti, K., Webb, D. R., & Davies, M. J. (2020) · Pharmaceuticals · doi:10.3390/ph13120427 · Cited by 54
Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus
Qiu, H., Rhoads, G. G., Berlin, J. A., Marcella, S. W., & Demissie, K. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12036 · Cited by 49
Remote control of glucose homeostasis in vivo using photopharmacology
Mehta, Z. B., Johnston, N. R., Nguyen‐Tu, M., Broichhagen, J., Schultz, P., Larner, D. P., Leclerc, I., Trauner, D. H., Rutter, G. A., & Hodson, D. J. (2017) · Scientific Reports · doi:10.1038/s41598-017-00397-0 · Cited by 46
Metformin Is Associated with Improved Survival and Decreased Cardiac Events with No Impact on Patency and Limb Salvage after Revascularization for Peripheral Arterial Disease
Khan, S. Z., Rivero, M., Nader, N. D., Cherr, G. S., Harris, L. M., Dryjski, M. L., & Dosluoglu, H. H. (2018) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2018.05.054 · Cited by 45
Differential Effects of Oral Hypoglycemic Agents on Glucose Control and Cardiovascular Risk
Uwaifo, G. I., & Ratner, R. E. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.006 · Cited by 43
Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms
Savarese, G., Butler, J., Lund, L. H., Bhatt, D. L., & Anker, S. D. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab271 · Cited by 45
Effect of metformin on the urinary metabolites of diet-induced-obese mice studied by ultra performance liquid chromatography coupled to time-of-flight mass spectrometry (UPLC-TOF/MS)
Zhu, Y.-Y., Feng, Y., Shen, L., De-sheng, X., Wang, B., Ruan, K., & Cong, W. (2013) · Journal of Chromatography B · doi:10.1016/j.jchromb.2013.02.040 · Cited by 41
Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus
Madsen, K. S., Kähler, P., Kähler, L. K. A., Madsbad, S., Gnesin, F., Metzendorf, M., Richter, B., & Hemmingsen, B. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012368.pub2 · Cited by 43
Cardiovascular Risk Associated With Acarbose Versus Metformin as the First-Line Treatment in Patients With Type 2 Diabetes: A Nationwide Cohort Study
Chang, C., Chang, Y., Lin, J., Chen, S., Chuang, L., & Lai, M. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2443 · Cited by 41
Is gliclazide a sulfonylurea with difference? A review in 2016
Singh, A. K., & Singh, R. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1159512 · Cited by 41
Defining the Role of Repaglinide in the Management of Type 2 Diabetes Mellitus
Johansen, O. E., & Birkeland, K. I. (2007) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200707050-00002 · Cited by 41
Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity/Mortality? Yes
Bianchi, C., Miccoli, R., Daniele, G., Penno, G., & Prato, S. D. (2009) · Diabetes Care · doi:10.2337/dc09-s336 · Cited by 40
Sulphonylurea–metformin combination therapy, cardiovascular disease and all‐cause mortality: the Fremantle Diabetes Study
Sillars, B. A., Davis, W. A., Hirsch, I. B., & Davis, T. M. E. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01230.x · Cited by 39
Diabetes and oral therapies
Alhadramy, M. S. (2016) · Journal of Taibah University Medical Sciences · doi:10.1016/j.jtumed.2016.02.001 · Cited by 40
Metformin associated lactic acidosis: a case series of 28 patients treated with sustained low-efficiency dialysis (SLED) and long-term follow-up
Angioi, A., Cabiddu, G., Conti, M. E., Pili, G., Atzeni, A., Matta, V., Cao, R., Floris, M., Songini, M., Mulas, M. F., et al. (2018) · BMC Nephrology · doi:10.1186/s12882-018-0875-8 · Cited by 38
Pharmacological management of type 2 diabetes: the potential of incretin‐based therapies
Charbonnel, B. H., & Cariou, B. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01317.x · Cited by 37
Cardiovascular risks associated with second‐line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study
Chang, Y., Chuang, L., Lin, J., Chen, S., Lai, M., & Chang, C. (2015) · Diabetic Medicine · doi:10.1111/dme.12800 · Cited by 36
Diagnosis and Treatment of Diabetic Kidney Disease
Gosmanov, A. R., Wall, B. M., & Gosmanova, E. O. (2014) · The American Journal of the Medical Sciences · doi:10.1097/maj.0000000000000185 · Cited by 38
Insulin Resistance: Pathophysiology and Rationale for Treatment
Muntoni, S., & Muntoni, S. (2011) · Annals of Nutrition and Metabolism · doi:10.1159/000323395 · Cited by 34
Discovery of a new molecule inducing melanoma cell death: dual AMPK/MELK targeting for novel melanoma therapies
Jaune, E., Cavazza, E., Ronco, C., Grytsai, O., Abbe, P., Tekaya, N., Zerhouni, M., Béranger, G. E., Kaminski, L., Bost, F., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-020-03344-6 · Cited by 35
Short-Term Continuous Subcutaneous Insulin Infusion Combined with Insulin Sensitizers Rosiglitazone, Metformin, or Antioxidant α-Lipoic Acid in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
Huang, Z., Wan, X., Liu, J., Deng, W., Chen, A., Liu, L., Liu, J., Wei, G., Li, H., Fang, D., et al. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0013 · Cited by 33
Multiple outcomes associated with the use of metformin and sulphonylureas in type 2 diabetes: a population-based cohort study in Italy
Corrao, G., Romio, S., Zambon, A., Merlino, L. G., Bosi, E., & Scavini, M. (2010) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-010-0939-6 · Cited by 31
Complementing Insulin Therapy to Achieve Glycemic Control
Barnett, A. H. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0039-y · Cited by 33
Evaluating Second-Line Treatment Options for Type 2 Diabetes: Focus on Secondary Effects of GLP-1 Agonists and DPP-4 Inhibitors
Boland, C. L., DeGeeter, M., Nuzum, D. S., & Tzefos, M. (2013) · Annals of Pharmacotherapy · doi:10.1345/aph.1r444 · Cited by 32
Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case‐control study
Azoulay, L., Schneider‐Lindner, V., Dell’Aniello, S., Schiffrin, A., & Suissa, S. (2010) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1834 · Cited by 31

Authors: Evans, J. M. M., Ogston, S. A., Emslie-Smith, A., & Morris, A. D.
Affiliations: University of Dundee (GB)
The Mill (GB)
Corresponding author: Evans, J. M. M.
ORCID: Evans, J. M. M.
Morris, A. D.
Venue: Diabetologia
Publisher: Springer Science and Business Media LLC
Published: 2006-03-09
Volume: 49
Issue: 5
Pages: 930-936
ISSN: 0012-186X (ISSN-L)
1432-0428
DOI: 10.1007/s00125-006-0176-9
OpenAlex: W2114349038
Cited by: 293
References: 19
Citations by year: 2026: 2 · 2025: 1 · 2024: 5 · 2023: 6 · 2022: 8 · 2021: 7 · 2020: 13 · 2019: 13 · 2018: 15 · 2017: 11 · 2016: 21 · 2015: 13 · 2014: 23 · 2013: 28 · 2012: 24
FWCI: 14.19
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.springer.com/tdm (tdm)
Locations: Diabetologia (publishedVersion)
PubMed (publishedVersion)
Discovery Research Portal (University of Dundee) (submittedVersion)
Stirling Online Research Repository (University of Stirling) (submittedVersion, public-domain)
Funders: Diabetes UK
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords: type 2 diabetes, sulfonylureas, metformin, oral antidiabetic drugs, cardiovascular mortality, all-cause mortality, cardiovascular hospital admissions, cardiovascular adverse events, combination therapy, newly treated patients
MeSH terms: Adult, Aged, Blood Pressure, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Drug Therapy, Combination, Female, Hospitalization, Humans, Male, Metformin, Middle Aged, Retrospective Studies, Risk Factors, Scotland, Sulfonylurea Compounds, Survival Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks